• The first oral Gonadotropin-Releasing Hormone (GnRH) Antagonist combined with add-back therapy in Europe, licensed specifically for Uterine Fibroids (UF)1

  • Balances efficacy and safety2-4

  • Significantly reduces heavy menstrual bleeding2
    >70% of women respond to Ryeqo2,5

  • Significantly reduces pain associated with UF2,6

  • Significant improvement in quality of life7

  • Inhibits ovulation and provides adequate contraception after one month of treatment1*

  • Established safety profile2,4

  • Bone health preserved during 104 weeks’ treatment1


  1. Ryeqo Summary of Product Characteristics.
  2. Al Hendy A et al. N Eng J Med 2021; 384:630-642.
  3. Al-Hendy A et al. ASRM, October 2020 O-1
  4. Al-Hendy A et al. ASRM, October 2019 O-1.
  5. Al-Hendy A et al. ASRM, October 2019 O-265.
  6. Al-Hendy A et al. Fertil Steril 2019;112(3):e434. Oral abstract O-265 presented at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress and Expo, Philadelphia, USA
  7. Al-Hendy A et al. ASRM, October 2020 O-205.

*Ryeqo inhibits ovulation in women taking the recommended dose and provides adequate contraception. Ovulation will return rapidly after discontinuing treatment.